Investigational triple-agonist peptide (GLP-1/GIP/glucagon) developed by Eli Lilly, researched for metabolic regulation, weight management, and glucose control.
Peptigrity tracks Retatrutide across 219 shops with 610 independent lab tests and an average HPLC purity of 99.65%.
Investigational triple-agonist peptide (GLP-1/GIP/glucagon) developed by Eli Lilly, researched for metabolic regulation, weight management, and glucose control.
Every submitted test helps the community verify purity across brands. Free, fast, independent.